EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 29,956 shares of common stock on 01/24/2024, as per the latest filing. The shares, valued at an aggregate market value of approximately $748,250, were acquired through open market purchases and restricted stock units (RSUs) on various dates ranging from February to June 2020, with payments made in cash or via stock options. Over the past three months, Lurker has sold a total of 25,044 shares, generating gross proceeds of over $541,000. The planned sale follows a pattern of recent transactions by Lurker, indicating a continued adjustment of her investment in the company.

EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 29,956 shares of common stock on 01/24/2024, as per the latest filing. The shares, valued at an aggregate market value of approximately $748,250, were acquired through open market purchases and restricted stock units (RSUs) on various dates ranging from February to June 2020, with payments made in cash or via stock options. Over the past three months, Lurker has sold a total of 25,044 shares, generating gross proceeds of over $541,000. The planned sale follows a pattern of recent transactions by Lurker, indicating a continued adjustment of her investment in the company.